Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
/
Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
Bactiquant A/S develops and provides advanced technology for the mobile and online surveillance of bacterial contamination levels in water. Its primary offerings include the Mobile Lab, a handheld tool designed for on-site pollution tracking, and BQ Online, an automated solution for continuous quantification of bacteria in water systems. These products enable near real-time monitoring of total bacterial mass, supporting proactive water quality control and efficient resource management. Bactiquant A/S serves diverse industries such as aquaculture, data centers, oil and gas, water utilities, general industry, and pharmaceuticals, helping clients optimize water usage, reduce waste, and ensure health and sustainability standards. The company's solutions facilitate in-line process control with rapid, reliable data and alerts for deviations from established baselines. Founded in 1999 and headquartered in Hørsholm, Denmark, Bactiquant A/S focuses on delivering precise bacterial quantification technology critical for modern water management across the treatment chain.
DKK 0.30
DKK 0.00 (-1.33%)
Live · 10:02 PM · Twelve Data
The business is unprofitable at the operating level (-150.24% margin). The thesis depends entirely on whether and when it reaches sustainable profitability.
Revenue up 15.9% YoY with margins expanding 26.0pp.
Negative free cash flow of -DKK 11M. The business is consuming cash, not generating it.
Based on TTM earnings · Diluted shares
Profitability & Returns
Revenue (TTM)
DKK 8M
▲ +15.9% YoY
Net Income (TTM)
-DKK 14M
▼ -0.8% YoY
Op. Margin
-150.24%
▲ +26.0pp YoY
ROIC
-52.16%
▲ +4.7pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
-DKK 11M
▲ +19.0% YoY
Op. Cash Flow (TTM)
-DKK 11M
▲ +16.8% YoY
Net Debt
-DKK 9M
Net Cash Position
Cash & Equiv.
DKK 18M
3Y CAGR: -12.4%
Continue Research
Bactiquant A/S (BACTIQ.XCSE)'s valuation is best read against its own history, its peers, and the growth its price implies. A high multiple is not the same as overvalued: fast-growing, high-quality businesses can deserve a premium. See the general approach in how to tell if a stock is overvalued.
On quality, Bactiquant A/S scores 10/100 on Intrinsiqq's quality scorecard (a lower-quality business on these measures), weighing growth, margins, returns on capital, share count, and balance-sheet strength. All figures are computed from SEC filings; read the full . This is analysis, not investment advice.
Bactiquant A/S scores 10 out of 100 on Intrinsiqq's quality score, a weighted blend of 6 metrics each scored 0 to 100, which makes it a lower-quality business on these measures. Recent fundamentals include a -150.2% operating margin and a -52.2% return on invested capital. The score weighs revenue and free-cash-flow growth, operating margins, return on invested capital, share-count change, and balance-sheet strength, all computed from SEC filings, not opinion. Because valuation only means something relative to quality, the full metric-by-metric breakdown is on the quality scorecard.
That depends on valuation and quality together, not either alone. you should weigh BACTIQ.XCSE's valuation and scores 10/100 on quality (lower-quality). A cheap price is only a bargain if the business is durable, and a premium can be justified by genuine quality, so the two questions, "is it cheap?" and "is it good?", only make sense side by side. Read the valuation against the quality scorecard, run the DCF on your own assumptions, and decide for yourself. This is analysis from SEC filings, not investment advice.